Neutralizing VEGF-A and blocking VEGF-D inhibit lymphangiogenesis during inflammation. (A-B) Footpad skin whole mounts from WT mice treated with control rat IgG, NIMP-R14, VEGF-A-neutralizing IgG, anti-VEGFR3 IgG, or a combination of VEGF-A-neutralizing IgG plus anti-VEGFR3 IgG were examined for lymphatic vessel network (A) and density (B) at 14 days postimmunization. (C) Footpad swelling in WT mice treated with control rat IgG, NIMP-R14, VEGF-A-neutralizing IgG, anti-VEGFR3 IgG, or a combination of VEGF-A-neutralizing IgG plus anti-VEGFR3 IgG. Images are representative of or pooled from 5 independent experiments (n = 5). Scale bars in panel A and panel C represent 100 μm and 2 mm, respectively. Bars represent mean ± SD. *P < .05; **P < .01.